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esponsibility of Xi'aAbstract Pioglitazone is an oral anti-hyperglycemic agent. It is used for the treatment of diabetes mellitus type
2. It selectively stimulates nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-gamma). It
was the tenth-best-selling drug in the U.S. in 2008. This article examines published analytical methods reported
so far in the literature for the determination of pioglitazone in biological samples and pharmaceutical
formulations. They include various techniques like electrochemical methods, spectrophotometry, capillary
electrophoresis, high-performance liquid chromatography, liquid chromatography–electrospray ionization-tandem
mass spectrometry and high-performance thin layer chromatography.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The active moiety of pioglitazone hydrochloride (PIO) (5-[[4-[2-(5-
ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione) is
a thiazolidinedione (Fig. 1), a potent and highly selective agonist for
the nuclear receptor, peroxisome proliferator-activated receptor gamma
(PPAR-γ). PPARs are found in tissues like adipose tissue, skeletal
muscle and liver, which are critical to insulin action. Activation of
PPAR-γ modulates the transcription of a number of insulin-responsive
genes involved in the control of glucose and lipid metabolism [1,2]. It
is not chemically or functionally related to the alpha-glucosidase
inhibitors, the biguanides, or the sulfonylureas. It addresses main
pathophysiological defect i.e., insulin resistance, so it is used alone or
in combination with insulin, metformin, or a sulfonylureas (glimepride
and glibenclamide) as an agent to treat diabetes. PIO reduces peripheralsity. Production and hosting by Elsev
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n Jiaotong University.and hepatic resistance to insulin, resulting in increased insulin‐
dependent glucose disposal and decreased hepatic glucose output
[3,4]. It has one chiral center and two enantiomers are available but no
differences are found in their activities. Hence racemic mixture is
pharmacologically used. Physically the hydrochloride salt of PIO is a
white crystalline powder with no odor and has a molecular formula of
C19H20N2O3S HCl. The molecular weight is 392.90 Da. It is admi-
nistered orally; insoluble in water and ether; slightly soluble in acetone,
acetonitrile and alcohol; and soluble in dimethylformamide (DMF) and
dimethyl sulfoxide (DMSO) [5,6]. In the present review we have
compiled the published analytical methods reported so far in the
literature for determination of PIO in biological samples and pharma-
ceutical formulations. Techniques like potentiometry, spectrophotome-
try, capillary electrophoresis (CE), high-performance liquid
chromatography (HPLC), liquid chromatography–mass spectrometry
(LC–MS) and high-performance thin layer chromatography (HPTLC)
have been used for analysis, from which HPLC methods are used most
extensively. Overview of these methods for determination of PIO is
shown in Fig. 2.ier B.V. All rights reserved.
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Fig. 1 Structure of pioglitazone.
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Fig. 2 Overview of analytical methods for estimation of pioglitazone
in biological and pharmaceutical samples. Fig. 3 Solubility chart of pioglitazone (generated using JMP
software).
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2.1. Solubility
According to Biopharmaceutics Classiﬁcation System (BCS),
classiﬁcation of PIO falls under BCS class-II [7], meaning it has
low solubility and high permeability. The solubility of the drug
was tested in solvents routinely used for analytical methodology
[8]. The solubility chart is shown in Fig. 3. To enhance aqueous
solubility of the drug, various strategies like co-solvent solubiliza-
tion [9], micellar solubilization [10], and cyclodextrin inclusion
complexes [11] have been proposed.
2.2. Sample preparation strategies
Sample preparation is an integral part of analytical methodology,
and it was reported that about approximately 30% error generated
in sample analysis was due to sample preparation [12]. Fig. 4
shows various diluents used for the analysis of PIO. In major
cases methanol was used as a diluent. The sample preparation
techniques for the extraction of PIO from biological matrices
(plasma, serum and urine) include protein precipitation with
acetonitrile, liquid–liquid extraction using diethyl ether, dichlor-
omethane, ethyl acetate, methyl t-butyl ether and n-butyl ether;
hollow ﬁber liquid phase micro-extraction using di n-hexyl ether;
and solid phase extraction.3. Analytical methods
3.1. Electrochemical methods
Mostafa et al. [13] constructed a new composite and classical
potentiometric sensor for the determination of PIO, in which the
authors used polyvinyl chloride (PVC) membrane sensors. These
membrane sensors incorporate ion association complexes of PIOcation and sodium tetraphenylborate (NaTPB) or phosphomolyb-
dic acid (PMA) or phosphotungstic acid (PTA) as electroactive
materials. Direct determination showed an average recovery of
98.5%, 99.0% and 98.4% correspondingly. These sensors were
applied for direct determination of PIO in some pharmaceutical
preparations and have been used as indicator electrodes for
potentiometric titration. In another study El-Ghobashy et al. [14]
applied the above proposed principle i.e. membrane selective
electrodes for the determination of PIO. The proposed method
showed a linear response over the concentration range 3.16
1051 102 M for PIO. The authors have applied this method
for the determination of PIO in tablets and plasma. Potentiometric
sensor for quantitative analysis of PIO was developed by Faridbod
et al. [15] who selected pioglitazone–tetraphenyl borate as a
suitable ion-pair reagent in making potentiometric PVC membrane
sensor for PIO. The proposed method showed a wide linear range
of 105–102 M and detection limit of 6.0 106 M. Badawy
et al. [16] quantiﬁed rosiglitazone, PIO, glimepiride and glyburide
conveniently and economically using cyclic voltammetry and
differential pulse voltammetry. The authors used carbon paste
and glassy carbon electrodes as sensors for these drugs in Briton–
Robinson as buffer solution. The proposed technique was found to
be orthogonal to the standard HPLC method. Ion selective
electrodes were prepared by construction of 10% standard drug
ionpair with reineckate or tungstophosphate imbedded as electro-
active material. Al-Arfaj et al. [17] used square-wave adsorptive
cathodic stripping voltammetry to determine PIO in Britton–
Robinson buffer of pH 5. The adsorptive cathodic peak was
observed at 1.5 V vs. Ag/AgCl. The detection limit was
8.08 109 M (3.17 ng/mL) using 300 s pre-concentration time.
This method was applied to assay in pharmaceutical formulations
and biological ﬂuids. The samples were extracted by liquid–liquid
extraction procedure using dichloromethane. The pharmacokinetic
parameters of PIO in human plasma were estimated as Cmax¼
785.8 ng/mL, tmax¼1.5 h, Ke¼0.125 h1 and t1/2¼8 h.
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In the literature about 22 methods were reported for the estimation
of PIO using spectrophotometry [8,18–34], of which 8 methods
are for determining PIO alone, while the others are for quantifying
PIO in combination with other drug substances. Table 1 shows the
summary of the reported spectrophotometric methods indicating
the basic principle, λmax, solvent and limit of detection (LOD).0 10 20 30 40
Methanol
0.1 M HCl
ACN: water (80:20, v/v)
Ethanol : water (80:20, v/v)
0.1% OPA : ACN (1:1, v/v)
Methanol : ACN (30: 70, v/v)
THF + aqueous phase
ACN
Ethanol 
0.1 M NaOH
No. of reported methods
Diluent
Fig. 4 Various diluents used for the analysis of pioglitazone.
Table 1 Representative spectrophotometric methods for the analysis
Compounds Method λmax Solvent/pr
PIO, SIT Vierodt's method 267, 269 0.1 M HC
PIO, MET,
GLP
Three wavelength method 236.5, 226.4,
227.3
Acetonitri
Multi-wavelength method 236.5, 226.4,
227.3, 254
PIO Extractive
spectrophotometric method
419 0.1 M HC
extracted
PIO, MET,
GLM
Second order derivative 265.4 Methanol
PIO, MET,
GLB
Absorption correction
method
268 Ethanol (9
PIO, GLM First order derivative 250 Methanol
PIO, ATS Vierodt's method 210, 225 Ethanol
PIO, GLP Vierodt's method 216, 225 0.1 M Na
Absorption ratio method 216, 228
PIO – 269 0.1 M HC
PIO – 224.4 Ethanol
PIO – 269 0.1 M HC
PIO, MET,
GLM
Vierodt's method 227, 233, 265.5 0.1 M Na
PIO Met. A 267 Ethanol:m
Met. B 297 Ion pair c
green (0.0
PIO, MET Vierodt's method 233, 265.5 0.1 M Na
PIO – 238 Phosphate
PIO, GLM Multi-wavelength
spectroscopy
238, 280 0.1 M Na
PIO, MET Difference spectrometric
method
225.8 Ethanolþ
PIO, MET Vierodt's method 225, 237 Methanol
Absorption correction
method
2673.3. Capillary electrophoresis (CE)
CE methods have excellent performance for separation of phar-
maceuticals, which makes it the ﬁrst-choice technique for separa-
tion of stereoisomers. For PIO analysis few authors have used CE
as a separation and determination technique. HPLC and micellar
electrokinetic chromatographic (MEKC) methods were developed
by Radhakrishna et al. [35] for the determination of PIO and its
unsaturated impurity was separated in less than 7 min using an
uncoated fused-silica capillary (43 cm 50 mm i.d.) with extended
light path for better sensitivity (25 kV at 30 1C) and a background
electrolyte consisting of 20% acetonitrile (v/v) in 0.02 M sodium
borate buffer pH 9.3 containing 0.05 M sodium dodecyl sulfate.
LOD and limit of quantiﬁcation (LOQ) were found to be 0.29 mg/
mL and 0.74 mg/mL, respectively.
Calixto et al. [36] proposed an alternative electrophoretic
method for PIO and its main metabolites determination in rat
liver microsomal fraction. It was carried out on an uncoated
fused-silica capillary (48 cm 50 mm i.d.) using 50 M sodium
phosphate buffer solution (pH 2.5). Using hydrodynamic
injection (0.05 bar, 15 s), samples were introduced into the
capillary and detected at 190 nm. The method demonstrated LOQ
of 200 ng/mL.of PIO.
ocedure LOD
(μg/mL)
Ref.
l 0.009 [8]
le:methanol:water (5:4:1) 0.18 [18]
0.18
l drugþBCG in pthalate buffer pH 2.4 and
into chloroform
– [19]
0.06 [20]
5%) 0.08 [21]
4 [22]
0.7 [23]
OH 0.04 [24]
0.05
l 0.66 [25]
– [26]
l 0.03 [27]
OH:Water (50:50) 0.007 [28]
ethanol:water – [29]
omplex with methyl orange and bromo cresol
5%)
–
OH 0.007 [30]
buffer pH 7.4 0.0002 [31]
OH – [32]
0.1 M NaOH – [33]
0.9 [34]
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3.4.1. HPLC
3.4.1.1. Biological samples. Various methods for the determina-
tion of PIO in biological samples like plasma, serum and urine
[37–43] are listed in Table 2.
3.4.1.2. Pharmaceutical samples. Analytical methods for the
determination of PIO in pharmaceutical dosages forms using
HPLC [35,44–67] are shown in Table 3, while Fig. 5 shows the
best HPLC methods for the analysis of PIO.
3.5. LC–MS
Ramulu et al. [68] have discussed the identiﬁcation, isolation and
characterization of potential degradation products using LC–MS,
1H NMR, 13C NMR, MS and IR. Oxidative degradation impurity
and base degradation impurity were characterized as pioglitazone
N-oxide, 3-(4-(2-(5-ethylpyridine-2yl)ethoxy) phenyl)-2-mercapto-
propanoic acid and 2-(1-carboxy-2-{4-[2-(5-ethylpyridine-2yl)-
ethoxy]phenyl}-ethyldisulfanyl)-3-{4-[2-(5-ethylpyridine-2yl)-
ethoxy] phenyl} propanoic acid respectively. The method consists
of water:triﬂuoroacetic acid in the ratio of 100:0.05 (v/v) as mobile
phase–A and acetonitrile:triﬂuoroacetic acid in the ratio of
100:0.05 (v/v) as mobile phase–B using gradient/elution (T/%B:
0/10, 12/62, 16/65,17/10) at a ﬂow rate of 1.0 mL/min and the
eluents are monitored at 225 nm. The separation was carried out
on a Zorbax Bonus RP18 column (150 mm 4.6 mm, 3.5 mm).
Zero air was used as nebulizer gas and high pure nitrogen was
used as curtain gas and collision assisted dissociation gas. The MS
parameters include Nebulizer 8.00 psi, curtain gas 8.00 psi, ion
spray voltage 4500 V, temperature 0 1C, declustering potential
70 V, focusing potential 180 V, and entrance potential 10 V.
A simple, high throughput, direct-injection (LC/MS/MS) method
was developed for the determination of PIO in human serum.
Extraction of samples was achieved on an Oasis HLB columnTable 2 Summary of HPLC methods to determine PIO in biologica
Matrix IS Sample
preparation
Mobile phase
Human serum AD-4875 Solid-phase and
liquid–liquid
extraction
MP-A; 0.05 M phosphate
buffer (pH 6.0)–methanol
(9:1, v/v)
and MP-B; 0.05 M phosphate
buffer (pH 6.0)–methanol–
ACN (4:2:4, v/v/v).
Human urine Liquid–liquid
extraction
Human plasma Rosaglitazone Solid-phase
extraction
Methanol:ACN:phosphate
buffer (pH 2.6; 0.01 M)
(40:12:48, v/v/v)
Human urine – Hollow ﬁber
liquid phase
micro-extraction
0.05 M ammonium acetate
(pH 4.6) and acetonitrile
(20/80, v/v)
Rat serum Rosaglitazone Protein
precipitation
using ethyl
acetate
Methanol and ammonium
acetate (0.03 M;
pH 5) (60:40, v/v).
Rat plasma – Liquid–liquid
extraction
Methanol and ammonium
acetate buffer (pH 3.5) (55:45)
Human plasma – Protein
precipitation
Phosphate buffer (pH 2.6;
0.01 M):methanol:ACN:
perchloric acid
Human serum Glibenclamide Protein
precipitation
Methanol–water–acetonitrile
(80:10:10, v/v/v)(50 mm 1 mm, 30 mm) with a 100% aqueous loading mobile phase
consisting of 0.005 M ammonium acetate (pH 4.0). The extracted
samples were eluted using a mobile phase consisting of 0.005 M
ammonium acetate and acetonitrile. The separation was carried out
on a Luna C18 column (50 mm 4.6 mm, 5 mm). Detection was
achieved by positive ion electrospray tandem mass spectrometry.
The lower limit of quantitation of the method was 9 ng/mL. The
linearity ranged from 9 to 1350 ng/mL. The authors have successfully
applied the proposed method to analyze PIO concentrations in human
serum samples for a bioequivalence study [69].
LC/MS/MS method was developed by Lin et al. [70]
for simultaneous determination of PIO and its two metabolites in
human plasma. Samples were extracted by single step liquid–liquid
extraction procedure using 1:1 (v/v) of methyl t-butyl ether:n-butyl
chloride. The extraction tubes were shaken at high speed for 20 min.
Elution of three components was done isocratically on a C18 column,
ionized using a positive ion atmospheric pressure electrospray
ionization source, and analyzed using multiple reactions monitoring
mode.
Another LC/MS/MS study was reported by Kumari Karra et al.
[71] for simultaneous determination of PIO and candesartan in
human plasma in which Irbesartan was used as an internal
standard. Solid phase extraction was used for extracting the
analytes from plasma. The samples were separated on a C18
column using a mixture of acetonitrile and 0.1% formic acid
(80:20, v/v) with a ﬂow rate of 0.8 mL/min. The proposed method
was linear in the range of 15–3000 ng/mL for PIO and was
successfully applied to human pharmacokinetic study.3.6. HPTLC
Dhirender Singh et al. [72] developed an HPTLC method for PIO.
They carried out separation on aluminum plates precoated with
silica gel using the mixture of toluene:ethyl acetate:formic acid
(10:3:1, v/v) as the mobile phase. The detection of spot was carriedl samples.
Column Detection λmax Flow
rate
(mL/min)
LOD/
LLOQ
(ng/mL)
Ref.
Inertsil ODS-2
(150 mm 4.6 mm, 5 μm)
UV 269 1 10 [37]
100
Apollo C18
(250 mm 4.6 mm, 5 μm)
UV 269 1.2 50 [38]
ODS-3 (150 mm 4.0 mm,
3 μm)
UV 270 0.7 1000 [39]
Phenomenex C18
(250 mm 4.6 mm, 5 μm)
UV 269 1 50 [40]
Phenomenex C18
(150 mm 4.6 mm, 5 mm)
UV 252 0.5 4 [41]
Shimpack VP-ODS
(150 mm 4.6 mm, 5 mm)
UV 269 1.5 50 [42]
Purospher STAR RP-18
(250 mm 4.6 mm, 5 μm)
UV 230 0.7 5000 [43]
Table 3 Reported analytical HPLC methods for determination of PIO either alone or in combination with other drugs like metformin
(MET), glimepiride (GLM), atorvastatin (ATS), glibenclamide (GLB), and gliclazide (GLC) in pharmaceutical dosage forms.
Study aim Mobile phase Column Detection λmax
(nm)
Flow rate
(mL/min)
LOD
(μg/mL)
Ref.
In bulk and pharmaceutical
formulations by HPLC and
MEKC methods
0.01 M potassium dihydrogen phosphate
buffer (pH 6.0):ACN (50:50, v/v)
Symmetry C18
(250 mm 4.6 mm, 5 μm)
UV 225 1 – [35]
SIAM by RP-HPLC Phosphate buffer (pH 4.0), ACN and
methanol (55:30:15, v/v)
Prontosil C8
(250 mm 4.6 mm, 5 μm)
UV 245 1.5 – [44]
Study of stressed degradation
behavior in bulk and
pharmaceutical formulation
0.01 M potassium dihydrogen phosphate
buffer (pH 3.5):methanol (55:45, v/v)
Phenomenex Luna C18
(250 mm 4.6 mm, 5 μm)
UV 241 1.5 1.69 [45]
Assay of tablets Ammonium formate buffer (pH 3):ACN
(75:25, v/v)
Nova-Pak C18
(150 mm 3.9 mm, 5 mm)
UV 225 1 – [46]
Purity test and assay of tablets Ammonium formate buffer (pH 4.1):ACN
(44:55, v/v)
Symmetry C18,
(250 mm 4.6 mm, 5 μm)
UV 266 1 0.042 [47]
SIAM ACN:(0.15, v/v) triethylamine (pH 4.6)
(40:60, v/v)
Hypersil C-8
(250 mm 4.6 mm, 5 μm)
UV 220 1.5 0.6 [48]
Simultaneous determination with
GLM
0.01 M triammonium citrate (pH 6.95):
ACN: methanol (45:35:20, v/v/v)
Cosmosil C18
(250 mm 4.6 mm, 5 μm)
UV 228 1 – [49]
Simultaneous with MET ACN:potassium dihydrogen phosphate
buffer (pH 3 ) (50:50, v/v)
Hypersil BDS C18
(250 mm 4.6 mm, 5 μm)
UV 238 1 – [50]
SIAM for determination of
impurities
ACN:0.05 M potassium dihydrogen
orthophosphate buffer of pH 3.0 (50:50, v/v)
Gemini C18
(250 mm 4.6 mm, 5 μm)
UV 225 1 0.005 [51]
Simultaneous determination with
GLM
ACN:0.02 M ammonium acetate (pH 4.5)
(60:40, v/v)
Inertsil ODS
(250 mm 4.6 mm, 5 μm)
UV 230 1 0.2 [52]
Simultaneous determination with
MET and GLM in tablet
formulation
Methanol:phosphate buffer (pH 4.3) (75:25,
v/v)
Inertsil-ODS-3 C-18
(250 mm 4.6 mm, 5 μm)
UV 258 1 – [53]
Simultaneous estimation with
saxagliptin in tablets
ACN:phosphate buffer (pH 7) (60:40, v/v) Inertsil C18 column
(250 mm 4.6 mm, 5 μm)
UV 260 0.8 0.010 [54]
Simultaneous determination with
GLM
ACN:0.01 M potassium dihydrogen
orthophosphate (pH 6.2) (50:50, v/v)
Eurosphere-100 C18
(250 mm 4.6 mm, 5 μm)
UV 225 1.4 0.00049 [55]
Simultaneous estimation with
GLM and rosiglitazone
Dil. orthophosphoric acid (pH 3.0):ACN
(80:20, v/v )
Nucleodur C-18
(250 mm 4.6 mm, 5 μm)
UV 215 0.8 0.19 [56]
Estimation along with MET in
tablets
ACN:water:acetic acid (75:25:0.3, v/v/v), pH
5.5
Hypersil ODS C18
(250 mm 4.6 mm, 5 μm)
UV 230 0.5 0.009 [57]
Simultaneous quantiﬁcation with
GLM and MET
Phosphate buffer:ACN:tetrahydrofuran
(40:50:10, v/v/v)
Intersil ODS 3V
(250 mm 4.6 mm, 5 μm)
UV 228 1.7 – [58]
Simultaneous estimation along
with GLM
Phosphate buffer:ACN (40:60, v/v) Inertsil ODS
(150 mm 4.6 mm, 5 μm)
UV 225 1.5 0.12 [59]
SIAM along with GLM Solution-A is 0.02 M potassium dihydrogen
phosphate, pH 3.2. Solution-B is ACN
Zorbaxcyano
(250 mm 4.6 mm, 5.0 μm )
UV 230 0.8 – [60]
Simultaneous determination with
metformin and GLC in
multicomponent formulation
Methanol:0.02 M potassium dihydrogen
phosphate (85:15, v/v)
C18 column
(250 mm 4.6 mm, 5.0 μm)
UV 227 1.2 0.1 [61]
Simultaneous estimation with
GLM
Methanol:water (72:28, v/v) Agilent TC – C18
(250 mm 4.6 mm, 5 μm)
UV 230 1 0.760 [62]
Simultaneous estimation with
telmisartan
ACN:ammonium dihydrogen phosphate (pH
4.5; 0.02 M) (65:35, v/v)
Phenomenex C8
(250 mm 4.6 mm, 5 μm)
UV 210 1 0.82 [63]
Determination of along with
metformin and GLM
ACN:phosphate buffer (pH 3) (65:35, v/v) Phenomenex RP-18
(150 mm 4.6 mm, 5 μm)
UV 245 0.5 0.061 [64]
Micellar liquid chromatographic
analytical method for
determination of atorvastatin
calcium
Tween-20: n-butanol: phosphate buffer, (pH
4.2) (50:25:25,v/v/v)
Luna C18
(250 mm 4.6 mm, 5 μm)
UV 322 1.5 – [65]
SIAM for determination of
impurities in PIO
Sol-A: phosphate buffer pH 3.1 and Sol-B:
acetonitrile
Inertsil ODS-3V
(150 mm 4.6 mm, 5 μm)
UV 225 1.5 0.033 [66]
HPLC method 0.01 M buffer:methanol (40:60, v/v) Symmetry – extend – C18
(150 mm 4.6 mm, 5 μm)
UV 240 1.2 – [67]
Pioglitazone: A review of analytical methods 299out at 254 nm. The calibration curve was found to be linear
between 100 and 3000 ng/mL. Gumieniczek et al. [73] reported a
thin‐layer chromatographic behavior of three antidiabetic drugs
PIO, rosiglitazone and repaglinide and then they developed
stability‐indicating HPTLC method for determination of PIO
in tablets. The mobile phase consisted of 1,4‐dioxane and
phosphate buffer of pH 4.4 (5:5). The detection was carried out
by densitometry at 266 nm. The proposed method was linear in therange of 0.4–2.4 mg/10 mL. Later Sharma et al. [74] gave an
HPTLC method for the determination of PIO and atorvastatin
using aluminum plates precoated with silica gel and mobile phase
consisting of chloroform:methanol:toluene (6:3:4, v/v). The detec-
tion was carried out at 259 nm. The calibration curve was found to
be linear between 100 and 400 ng/spot for both drugs. In another
study, Anand et al. [75] proposed an HPTLC method for
determination of PIO along with telmesartan using the mobile
Fig. 5 Sensitive and greener HPLC methods among the reported.
Fig. 6 Comparison of sensitivities of various techniques for estima-
tion of pioglitazone.
N. Satheeshkumar et al.300phase consisting of toluene:ethyl acetate:methanol (7:2:1, v/v/v).
LOD and LOQ were 140.0, 186.7 and 424.4, 1867.5 ng/spot for
telmesartan and PIO respectively. Kale et al. [76] proposed a
simple HPTLC method for simultaneous estimation of PIO, MET,
and GLP using mobile phase consisting of acetonitrile, methanol,
propyl alcohol, and ammonium acetate 7:2:1:1 (v/v). Densito-
metric quantiﬁcation was performed at 240 nm. The Rf value of
PIO was found to be 0.83 and the method was linear in the range
of 0.3–1.2 μg/band. The comparative sensitivities of various
techniques are shown in Fig. 6.4. Challenges
As discussed earlier, PIO belongs to BCS class-II and so it is
insoluble in water. Selection of the diluents would be a problem in
the analysis of PIO as there are concerns with the formation of
insoluble precipitate with various compositions of aqueous:organic
phases. Furthermore, with more amount of aqueous phase or
methanol in the mobile phase, the run times are prolonged with
greater tailing factor in HPLC. It was observed that the drug gets
slowly degraded in strongly acidic conditions over a period of
time. For spectrometric determination, complexity with multi-
component dosage forms includes the presence of multiple entities
and excipients, which may cause considerable challenge to the
analytical chemist during the development of assay procedure.
Estimation of the individual drugs in these multicomponent dosage
forms becomes difﬁcult. For such instances like multicomponentdosage forms, chemometric methods can be preferred to routine
spectrophotometric methods.5. Conclusion
In conclusion, a broad range of techniques are available for the
analysis of PIO in biological samples and pharmaceutical for-
mulations. The analysis of the published data revealed that the
HPLC was extensively used for the determination of PIO in
various matrices like plasma, serum and urine. For determination
of PIO in biological samples, we recommend the HPLC–MS/MS
method, since this method combines the HPLC separation ability
with MS sensitivity and selectivity, allowing the unambiguous
identiﬁcation of PIO and its metabolites. For analysis of PIO in
pharmaceuticals, HPLC with UV detection is applicable because
this method provides accurate results and low cost compared to
more advanced detection techniques. This review carried out an
overview of the current state-of-art analytical methods for the
determination of PIO.Acknowledgments
The authors wish to thank Dr. Ahmed Kamal, Project Director,
National Institute of Pharmaceutical Education & Research,
Hyderabad for his constant encouragement. One of the author
Mr. Shanti Kumar is thankful to the Department of Pharmaceu-
ticals, Ministry of Chemicals and Fertilizers, New Delhi, India for
providing a research fellowship.References
[1] G. Belcher, C. Lambert, G. Edwards, et al., Safety and tolerability of
pioglitazone, metformin, and gliclazide in the treatment of type 2
diabetes, Diabetes Res. Clin. Pract. 70 (2005) 53–62.
[2] J.M. Olefsky, Treatment of insulin resistance with peroxisome
proliferator-activated receptor gamma agonists, J. Clin. Invest. 106
(2000) 467–472.
Pioglitazone: A review of analytical methods 301[3] Y. Miyazaki, L. Glass, C. Triplitt, et al., Effect of rosiglitazone on
glucose and non-esteriﬁed fatty acid metabolism in type II diabetic
patients, Diabetologia 44 (2001) 2210–2219.
[4] Y. Miyazaki, A. Mahankali, M. Matsuda, et al., Improved glycemic
control and enhanced insulin sensitivity in type 2 diabetic subjects
treated with pioglitazone, Diabetes Care 24 (2001) 710–719.
[5] G. Iacobellis, Drug–Drug Interactions in the Metabolic Syndrome,
Nova Science Publishers, New York, 2006.
[6] K. Mizushige, T. Tsuji, T. Noma, Pioglitazone: cardiovascular effects
in prediabetic patients, Cardiovasc. Drug Rev. 20 (2002) 329–340.
[7] K.P.R. Chowdary, D.U. Chandra, N. Mahesh, et al., Enhancement of
dissolution rate and formulation development of pioglitazone-a BCS
class II drug, J. Pharm. Res. 4 (2011) 3862–3863.
[8] S.S. Kumar, Y. Krishnaveni, G. Ramesh, Simultaneous estimation of
sitagliptin and pioglitazone by UV-spectroscopic method and study of
interference of various excipients on this combination of drugs, Int. J.
Curr. Pharm. Res. 4 (2012) 113–116.
[9] N. Seedher, M. Kanojia, Co-solvent solubilization of some poorly-
soluble antidiabetic drugs, Pharm. Dev. Technol. 14 (2009) 185–192.
[10] N. Seedher, M. Kanojia, Micellar solubilization of some poorly
soluble antidiabetic drugs: a technical note, AAPS Pharm. SciTech 9
(2008) 431–436.
[11] V. Pandit, R. Gorantla, K. Devi, et al., Preparation and characteriza-
tion of pioglitazone cyclodextrin inclusion complexes, J. Young
Pharm. 3 (2011) 267–274.
[12] M.M.W.B. Hendriks, J.H. de Boer, A.K. Smilde, Robustness of
Analytical Chemical Methods and Pharmaceutical Technological
Products, Elsevier, Netherlands, 1996.
[13] G.A. Mostafa, A. Al-Majed, Characteristics of new composite-and
classical potentiometric sensors for the determination of pioglitazone
in some pharmaceutical formulations, J. Pharm. Biomed. Anal. 48
(2008) 57–61.
[14] M. El-Ghobashy, A. Yehia, A. Mostafa, Application of membrane-
selective electrodes for the determination of pioglitazone HCl in the
presence of its acid degradant or metformin HCl in tablets and
plasma, Anal. Lett. 42 (2009) 123–140.
[15] F. Faridbod, M.R. Ganjali, E. Nasli-Esfahani, et al., Potentiometric
sensor for quantitative analysis of pioglitazone hydrochloride in
tablets based on theoretical studies, Int. J. Electrochem. Sci. 5
(2010) 880–894.
[16] W.A. Badawy, M.A. El-Ries, I.M. Mahdi, Carbon paste-and PVC
membrane electrodes as sensitive sensors for the determination of
antidiabetic drugs for type 2 diabetic patients, Anal. Sci. 25 (2009)
1431–1436.
[17] N.A. Al-Arfaj, E.A. Al-Abdulkareem, F.A. Aly, Flow-injection
chemiluminometric determination of pioglitazone HCl by its sensitiz-
ing effect on the cerium-sulﬁte reaction, Anal. Sci. 25 (2009)
401–406.
[18] L. Adhikari, S. Jagadev, S. Sahoo, et al., Devlopement and validation
of UV–visible spectrophotometric method for simultaneous determi-
nation of pioglitazone HCl, metformin HCl and glipizide in its bulk
and pharmaceutical dosage form (tablet), Int. J. ChemTech Res. 4
(2012) 625–630.
[19] M. Amanlou, M. Zarei-Ghobadi, M.K. Rofouei, et al., Extractive
spectrophotometric method for determination of pioglitazone HCl in
raw material and tablets using ion-pair formation, J. Chem. 7 (2010)
915–921.
[20] P. Deepa, P. Laxmanbhai, P. Madhabhai, et al., Simultaneous
estimation of glimepiride, pioglitazone HCl and metformin HCl by
derivative spectrophotometry method, Int. Res. J. Pharm. 2 (2011)
111–114.
[21] S.M. Dhole, P.B. Khedekar, N.D. Amnerkar, UV spectrophotometric
absorption correction method for the simultaneous estimation of
pioglitazone HCl, metformin HCl and glibenclamide in multicompo-
nent formulation, Int. J. Anal. Bioanal. Chem. 3 (2013) 18–22.
[22] M.D. Game, First order derivative spectrophotometric method for
simultaneous estimation of glimepiride and pioglitazone HCl in
combined dosage form, J. Pharm. Res. 4 (2011) 4301–4302.[23] O.S. Havele, S.S. Havele, Simultaneous determination of atorvastatin
calcium and pioglitazone hydrochloride in its multicomponent dosage
forms by UV spectrophotometry, Int. J. Pharm. Sci. Res. 1 (2011) 75–79.
[24] L. Kishore, N. Kaur, Estimation of pioglitazone and glimipride in its
pharmaceutical dosage form by spectrophotometric methods, Der
Pharm. Lett. 3 (2011) 276–284.
[25] S.P. Mahadik, G.P. Senthilkumar, Method development & validation
of pioglitazone in bulk and pharmaceutical dosage forms by using
spectrophotometric method, Asian J. Biochem. Pharm. Res. 2 (2012)
159–165.
[26] M. Younus Ali, P.V. Swamy, P. Borgaonkar, et al., UV-spectro-
photometric determination of pioglitazone in pharmaceutical dosage
forms, Int. J. Chem. Sci. 6 (2008) 2062–2065.
[27] S. Mohd, A.P. Kulkarni, Z. Zaheer, et al., Spectroscopic estimation of
pioglitazone hydrochloride, Int. J. Pharm. Frontier Res. 2 (2012) 87–94.
[28] P. Pallavi, R. Sonali, C. Praveen, Development and validation of UV
derivative spectrophotometric methods for the determination of
glimepiride, metformin HCl and pioglitazone HCl in bulk and
marketed formulation, J. Pharm. Sci. Innov. 1 (2012) 58–62.
[29] S. Patil, S. Dwivedi, S. Bagade, Development of spectrophotometric
method for the estimation of pioglitazone HCl from two different
marketed brands, Am. J. PharmTech Res. 1 (2011) 264–275.
[30] S.D. Rathod, P.M. Patil, S.B. Jadhav, et al., UV-spectrophotometric
simultaneous determination of metformin HCl and pioglitazone HCl
in combined dosage form, Asian J. Pharm. Anal. 2 (2012) 05–09.
[31] P. Shakya, K. Singh, Determination of pioglitazone hydrochloride in
bulk and pharmaceutical formulations by UV spectrophotometric
method, Int. J. Pharm. Sci. Res. 1 (2010) 153–157.
[32] I. Singhvi, K. Mehta, N. Kapadiya, Analytical method development
and validation for the simultaneous estimation of pioglitazone and
glimepiride in tablet dosage form by multiwavelength spectroscopy, J.
Appl. Pharm. Sci. 1 (2011) 159–161.
[33] K. Sujana, K. Abbulu, O.B. Souri, et al., Difference spectrophoto-
metric methods for pioglitazone HCl and metformin HCl, J. Pharm.
Sci. Res. 3 (2011) 1122–1126.
[34] K. Sujana, G.S. Rani, M.B. Prasad, et al., Simultaneous estimation of
pioglitazone HCl and metformin HCl using UV spectroscopic
method, J. Biomed. Sci. Res. 2 (2010) 110–115.
[35] T. Radhakrishna, D. Sreenivas Rao, G. Om Reddy, Determination of
pioglitazone hydrochloride in bulk and pharmaceutical formulations
by HPLC and MEKC methods, J. Pharm. Biomed. Anal. 29 (2002)
593–607.
[36] L.A. Calixto, P.S. Bonato, Combination of hollow-ﬁber liquid-phase
microextraction and capillary electrophoresis for pioglitazone and its
main metabolites determination in rat liver microsomal fraction,
Electrophoresis 34 (2013) 862–869.
[37] K. Yamashita, H. Murakami, O. Teruaki, et al., High-performance
liquid chromatographic determination of pioglitazone and its meta-
bolites in human serum and urine, J. Chromatogr. B Anal. Technol.
Biomed. Life Sci. 677 (1996) 141–146.
[38] P. Sripalakit, P. Neamhom, A. Saraphanchotiwitthaya, High-
performance liquid chromatographic method for the determination
of pioglitazone in human plasma using ultraviolet detection and its
application to a pharmacokinetic study, J. Chromatogr. B Anal.
Technol. Biomed. Life Sci. 843 (2006) 164–169.
[39] E. Tahmasebi, Y. Yamini, A. Saleh, Extraction of trace amounts of
pioglitazone as an anti-diabetic drug with hollow ﬁber liquid phase
microextraction and determination by high-performance liquid
chromatography-ultraviolet detection in biological ﬂuids, J. Chroma-
togr. B Analt. Technol. Biomed. Life Sci. 877 (2009) 1923–1929.
[40] C.H. Ravikanth, A.A. Kumar, V.U. Kiran, et al., Sensitive and rapid
HPLC method for the determination of pioglitazone in rat serum, Int.
J. Pharm. Sci. Drug Res. 3 (2011) 38–41.
[41] K.S. Lakshmi, T. Rajesh, S. Sharma, Determination of pioglitazone
and glimepiride in pharmaceutical formulations and rat plasma by
RP-LC, Int. J. PharmTech Res. 1 (2009) 496–499.
[42] Z. Islambulchilar, H. Valizadeh, P. Zakeri-Milani, Rapid HPLC
determination of pioglitazone in human plasma by protein
N. Satheeshkumar et al.302precipitation and its application to pharmacokinetic studies, J. AOAC
Int. 93 (2010) 876–881.
[43] M.S. Arayne, N. Sultana, A.Z. Mirza, Simultaneous determination of
gliquidone, pioglitazone HCl, and verapamil in formulation and
human serum by RP-HPLC, J. Chromatogr. Sci. 49 (2011) 114–117.
[44] G.R.K. Reddy, V.S.N. Rao, Development and validation of stability
indicating assay method for pioglitazone drug substance by reverse
phase HPLC, J. Global Trends Pharm. Sci. 3 (2012) 584–596.
[45] S. Sharma, M.C. Sharma, S.C. Chaturvedi, Study of stressed
degradation behavior of pioglitazone hydrochloride in bulk and
pharmaceutical formulation by HPLC assay method, J. Optoelectron.
Biomed. Mater. 1 (2010) 17–24.
[46] A.M.R.L. Saber, Determination of pioglitazone hydrochloride in
tablets by high-performance liquid chromatography, Pak. J. Anal.
Environ. Chem. 9 (2008) 118–121.
[47] A. Jedlicka, J. Klimes, T. Grafnetterova, Reversed-phase HPLC
methods for purity test and assay of pioglitazone hydrochloride in
tablets, Pharmazie 59 (2004) 178–182.
[48] D.B. Wanjari, N.J. Gaikwad, Stability indicating RP-HPLC method
for determination of pioglitazone from tablets, Indian J. Pharm. Sci.
67 (2005) 256–258.
[49] R.T. Sane, S.N. Menon, S. Inamdar, et al., Simultaneous determina-
tion of pioglitazone and glimepiride by high-performance liquid
chromatography, Chromatographia 59 (2004) 451–453.
[50] J. Swapna, C. Madhu, M. Srivani, et al., Analytical method devel-
opment and method validation for the simultaneous estimation of
metformin hydrochloride and pioglitazone hydrochloride in tablet
dosage form by RP-HPLC, Asian J. Pharm. Anal. 2 (2012) 85–89.
[51] V. Sriram, K. Sriram, J. Angirekula, et al., Development and
validation of stability indicating reverse phase HPLC method for
the determination of impurities in pioglitazone hydrochloride, Int. J.
Pharm. Biomed. Sci. 3 (2012) 89–96.
[52] A. Karthik, G. Subramanian, C.M. Rao, et al., Simultaneous
determination of pioglitazone and glimepiride in bulk drug and
pharmaceutical dosage form by RP-HPLC method, Pak. J. Pharm.
Sci. 21 (2008) 421–425.
[53] D. Jain, S. Jain, D. Jain, et al., Simultaneous estimation of metformin
hydrochloride, pioglitazone HCl, and glimepiride by RP-HPLC in
tablet formulation, J. Chromatogr. Sci. 46 (2008) 501–504.
[54] M. Sarat, P.M. Krishna, C. Rambabu, RP-HPLC method for estima-
tion of saxagliptin and pioglitazone in tablets, Int. Res. J. Pharm. 3
(2012) 399–402.
[55] T.M. Kalyankar, M.R. Badgujar, R.B. Kakde, Simultaneous determi-
nation of pioglitazone HCl and glimepiride by RP-HPLC in pharma-
ceutical dosage form, J. Pharm. Res. 3 (2010) 3078–3080.
[56] F.H. Havaldar, D.L. Vairal, Simultaneous estimation of glimepiride,
rosiglitazone and pioglitazone hydrochloride in the pharmaceutical
dosage form, J. Chem. 7 (2010) 1326–1333.
[57] M.B. Shankar, V.D. Modi, D.A. Shah, et al., Estimation of pioglitazone
hydrochloride and metformin hydrochloride in tablets by derivative
spectrophotometry and liquid chromatographic methods, J. AOAC Int.
88 (2005) 1167–1172.
[58] G. Nirupa, U.M. Tirupathi, RP-HPLC analytical method development
and validation for simultaneous estimation of three drugs: glimepride,
pioglitazone and metformin and its pharmaceutical dosage forms,
J. Chem. 2013 (2013) 1–8.
[59] M.S.V. Sakuntala, S.V.U.M. Prasad, S.S. Devi, et al., A RP-HPLC
method development and validation for the simultaneous estimation
of glimepiride and pioglitazone HCl in tablet dosage forms, J. Chem.
Pharma. Res. 4 (2012) 154–159.
[60] G. Navaneethan, K. Karunakaran, K.P. Elango, Simultaneous estima-
tion of pioglitazone, glimepiride and glimepiride impurities incombination drug product by a validated stability-indicating
RP-HPLC method, J. Chil. Chem. Soc. 56 (2011) 815–818.
[61] H. Shweta, S. Dhaneshwar, Development and validation of a HPLC
method for the determination of metformin HCl, gliclazide and
piogliglitazone hydrochloride in multicomponent formulation,
Webmed Central Pharm. Sci. 1 (2010) 1–16.
[62] V. Kumar, M. Sudhakar, Y. Padmanabha Reddy, et al., Method
development and validation for simultaneous estimation of pioglita-
zone and glimepiride in tablet dosage form by RP-HPLC and UV-
spectrophotometric method, Curr. Pharm. Res. 2 (2011) 404–410.
[63] D.C. PremAnand, K.L. Senthilkumar, B. Senthilkumar, et al., A new
RP-HPLC method development and validation for simultaneous
estimation of telmisartan and pioglitazone in pharmaceutical dosage
form, Int. J. ChemTech Res. 3 (2009) 448–454.
[64] K.S. Lakshmi, T. Rajesh, S. Sharma, et al., Development and
validation of liquid chromatographic and UV derivative spectro-
photometric methods for the determination of metformin, pioglitazone
and glimepiride in pharmaceutical formulations, Der. Pharm. Chem. 1
(2009) 238–246.
[65] M.C. Sharma, S. Sharma, D.V. Kohli, et al., Micellar liquid
chromatographic analytical method development and validation of
determination of atorvastatin calcium and pioglitazone in tablet
dosage form, Der. Pharm. Chem. 2 (2010) 273–280.
[66] N. Rashmithaa, S.G. Hiriyanna, C.H.S. Rao, A validated stability
indicating HPLC method for the determination of impurities in
pioglitazone hydrochloride, Der. Pharm. Chem. 2 (2010) 426–433.
[67] A. Madhukar, K. Naresh, C.N. Kumar, et al., Rapid and sensitive RP-
HPLC analytical method development and validation of pioglitazone
hydrochloride, Der. Pharm. Chem. 3 (2011) 128–132.
[68] K. Ramulu, T.T. Kumar, S.R. Krishna, et al., Identiﬁcation, isolation
and characterization of potential degradation products in pioglitazone
hydrochloride drug substance, Pharmazie 65 (2010) 162–168.
[69] Y.-J. Xue, K.C. Turner, J.B. Meeker, et al., Quantitative determina-
tion of pioglitazone in human serum by direct-injection high-
performance liquid chromatography mass spectrometry and its
application to a bioequivalence study, J. Chromatogr. B Anal.
Technol. Biomed. Life Sci. 795 (2003) 215–226.
[70] Z.J. Lin, W. Ji, D. Desai-Krieger, et al., Simultaneous determination
of pioglitazone and its two active metabolites in human plasma by
LC–MS/MS, J. Pharm. Biomed. Anal. 33 (2003) 101–108.
[71] V. Kumari Karra, N. Rao Pilli, J. Kumar Inamadugu, et al.,
Simultaneous determination of pioglitazone and candesartan in
human plasma by LC-MS/MS and its application to a human
pharmacokinetic study, J. Pharm. Anal. 2 (2012) 167–173.
[72] S.C.D. Dhirender Singh, Ashok Kushnoor, Development and valida-
tion of a HPTLC method for estimation of pioglitazone in bulk and
tablet dosage form, J. Pharm. Res. 4 (2011) 3919–3921.
[73] A. Gumieniczek, H. Hopkała, A. Berecka, Reversed‐phase thin‐layer
chromatography of three new oral antidiabetics and densitometric
determination of pioglitazone, J. Liq. Chromatogr. Relat. Technol. 27
(2005) 2057–2070.
[74] M. Sharma, S. Sharma, D. Kohli, HPTLC method development and
validation for the estimation of atorvastatin calcium and pioglitazone
HCl in pharmaceutical combined tablet dosage form, Ann. Biol. Res.
1 (2010) 124–129.
[75] D.P. Anand, HPTLC method for determination of telmesarton HCl
with pioglitazone HCl in pharmaceutical dosage form, Int. J. Pharm.
Res. 2 (2010) 185–190.
[76] D. Kale, R. Kakde, Simultaneous determination of pioglitazone,
metformin, and glimepiride in pharmaceutical preparations using
HPTLC method, J. Planar Chromatogr. Mod. TLC 24 (2011) 331–
336.
